-
Journal for ImmunoTherapy of Cancer. Clinicopathologic, genomic and immunotypic features and outcomes to immune checkpoint inhibitors in patients with mucinous lung adenocarcinoma. 2023. View in:
Pubmed
-
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nat Med. 2023 Dec 05. View in:
Pubmed
-
The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma. Cancer Res. 2023 Dec 01; 83(23):3846-3860. View in:
Pubmed
-
EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes. Cancer Res. 2023 Dec 01; 83(23):3956-3973. View in:
Pubmed
-
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 11 01; 29(21):4408-4418. View in:
Pubmed
-
Proceedings Association for Molecular Pathology (AMP) Annual Meeting. Multiomic characterization and molecular profiling of NUT carcinoma. 2023. View in:
Pubmed
-
Proceedings AACR-NCI-EORTC. A first-in-human study of CDK9 inhibitor KB-0742 demonstrates evidence of tolerability and clinical activity. 2023. View in:
Pubmed
-
ASCO Proceedings. Initial chemotherapy for locally advanced and metastatic NUT carcinoma: A report from the NUT carcinoma registry. 2023. View in:
Pubmed
-
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC. J Thorac Oncol. 2023 11; 18(11):1524-1537. View in:
Pubmed
-
Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma. Ann Oncol. 2023 07; 34(7):589-604. View in:
Pubmed
-
Thoracic Malignancies. Pocket oncology. Third edition / edited by Drilon, A. Vasan, N, Choudhury, N, Murciano-Goroff, YR. 2022. View in:
Pubmed
-
Phase I trial of the TNF-a inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. Nat Commun. 2022 10 15; 13(1):6095. View in:
Pubmed
-
Safety of image guided research biopsies in patients with thoracic malignancies. Lung Cancer. 2022 11; 173:53-57. View in:
Pubmed
-
Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. Nat Cancer. 2022 10; 3(10):1151-1164. View in:
Pubmed
-
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann Oncol. 2022 10; 33(10):1029-1040. View in:
Pubmed
-
Deciphering radiological stable disease to immune checkpoint inhibitors. Ann Oncol. 2022 08; 33(8):824-835. View in:
Pubmed
-
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience. JTO Clin Res Rep. 2022 Jun; 3(6):100328. View in:
Pubmed
-
Overcoming KRAS-Mutant Lung Cancer. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-11. View in:
Pubmed
-
Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. J Thorac Oncol. 2021 10; 16(10):1759-1764. View in:
Pubmed
-
Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 09 15; 27(18):5131-5140. View in:
Pubmed
-
Association of prior radiation dose to the cardiopulmonary system with COVID-19 outcomes in patients with cancer. Radiother Oncol. 2021 08; 161:115-117. View in:
Pubmed
-
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. J Immunother Cancer. 2021 02; 9(2). View in:
Pubmed
-
Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor. JCO Precis Oncol. 2021; 5. View in:
Pubmed
-
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade. Cancer Discov. 2021 01; 11(1):59-67. View in:
Pubmed
-
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 2020 12; 10(12):1842-1853. View in:
Pubmed
-
Outcomes to first-line pembrolizumab in patients with PD-L1-high (=50%) non-small cell lung cancer and a poor performance status. J Immunother Cancer. 2020 08; 8(2). View in:
Pubmed
-
COVID-19 in patients with lung cancer. Ann Oncol. 2020 10; 31(10):1386-1396. View in:
Pubmed
-
MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol. 2020 09; 17(9):569-587. View in:
Pubmed
-
Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. Cancer Discov. 2020 08; 10(8):1121-1128. View in:
Pubmed
-
Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-12. View in:
Pubmed
-
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clin Cancer Res. 2020 06 15; 26(12):2849-2858. View in:
Pubmed
-
A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda. J Cancer Res Clin Oncol. 2019 Sep; 145(9):2303-2311. View in:
Pubmed
-
Management of Localized Breast Angiosarcoma by North American Radiation and Medical Oncologists. Clin Breast Cancer. 2018 12; 18(6):498-503. View in:
Pubmed
-
A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. Eur J Cancer. 2018 09; 101:143-151. View in:
Pubmed
-
Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. Res Rep Urol. 2016; 8:217-224. View in:
Pubmed
-
Current Patterns of Care for Patients with Extensive-Stage SCLC: Survey of U.S. Radiation Oncologists on Their Recommendations Regarding Prophylactic Cranial Irradiation. J Thorac Oncol. 2016 08; 11(8):1305-1310. View in:
Pubmed
-
AMP-Activated Protein Kinase Directly Phosphorylates and Destabilizes Hedgehog Pathway Transcription Factor GLI1 in Medulloblastoma. Cell Rep. 2015 Jul 28; 12(4):599-609. View in:
Pubmed
-
Symptoms and palliative care needs of pancreatic adenocarcinoma patients. J Palliat Med. 2014 Jun; 17(6):640-1. View in:
Pubmed